ReviewDrug delivery and translational research2023
Microneedle-mediated treatment for superficial tumors by combining multiple strategies.
Review in Drug delivery and translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- ROS-responsive tegafur-pheophorbide a conjugate-loaded microneedles for deep drug delivery and chemo-photodynamic therapy of superficial tumors.International journal of pharmaceutics: X · 2026Article
- 3D-Printed Microneedle Patch for the Treatment of Melanoma via Synergistic Chemotherapy and Photothermal Therapy.ACS applied bio materials · 2026Article
- Advances in 3D Printed Microneedles as a Prototype for Skin Targeted Therapeutics in Personalized Dermal Pharmaceuticals.AAPS PharmSciTech · 2025Review
- The application prospect of microneedles for sports injuries: a narrative review.Annals of medicine · 2025Review
- Microneedles as Gateways: Smart Nanoparticle Delivery for Enhanced Breast Cancer Treatment.ACS omega · 2025Review
- Application of NIR Fluorescent Materials in Imaging and Treatment of Tumors of Different Depths.Nanomaterials (Basel, Switzerland) · 2025Review
- Microneedle-Assisted Delivery of Curcumin: Evaluating the Effects of Needle Length and Formulation.Micromachines · 2025Article
- An Overview of Microneedles as a Drug Delivery System.Current pharmaceutical design · 2025Article
- Advancing Melanoma Care: Microneedles for Diagnosis and Therapeutic Precision.Current pharmaceutical design · 2025Review
- Dissolvable Microneedle Administration Combined with Ultrasonic Cavitation Promotes Melanoma Penetrating Capability of Ce6.International journal of nanomedicine · 2025Article
- Microneedles as an Emerging Platform for Transdermal Delivery of Phytochemicals.Molecular pharmaceutics · 2024Review
- Development of Quercetin Solid Dispersion-Loaded Dissolving Microneedles and In Vitro Investigation of Their Anti-Melanoma Activities.Pharmaceutics · 2024Article
- Nanocomposite hydrogel microneedles: a theranostic toolbox for personalized medicine.Drug delivery and translational research · 2024Review
- Innovative Topical Patches for Non-Melanoma Skin Cancer: Current Challenges and Key Formulation Considerations.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superficial tumors are still challenging to overcome due to the high risk and toxicity of surgery and conventional chemotherapy. Microneedles (MNs) are widely used in the treatment of superficial skin tumors (SST) due to the high penetration rate of the stratum corneum (SC), excellent biocompatibility, simple preparation process, high patient compliance, and minimal invasion. Most importantly, MNs can provide not only efficient and rarely painful delivery carriers, but also combine multi-model strategies with photothermal therapy (PTT), immunotherapy, and gene therapy for synergistic efficacy. To promote an in-depth understanding of their superiorities, this paper systematically summarized the latest application progress of MNs in the treatment of SST by delivering various types of photosensitizers, immune signal molecules, genes, and chemotherapy drugs. Just as important, the advantages, limitations, and drug release mechanisms of MNs based on different materials are introduced in the paper. In addition, the application of MN technology to clinical practice is the ultimate goal of all the work. The obstacles and possible difficulties in expanding the production of MNs and achieving clinical transformation are briefly discussed in this paper. To be anticipated, our work will provide new insights into the precise and rarely painful treatment of SST in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.